Glenmark Pharmaceuticals Ltd vs Speciality Medicines Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 13, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2255 as of 12 May 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Speciality Medicines Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Speciality Medicines Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The revenue of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The ebitda of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The net profit of Speciality Medicines Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Speciality Medicines Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Speciality Medicines Ltd

Speciality Medicines Limited was originally incorporated as 'Speciality Medicines Private Limited' as a Private Limited Company, dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre.
Later on, the status was converted to Public Limited and the name of the Company was changed to 'Speciality Medicines Limited' and a fresh Certificate of Incorporation dated June 25, 2024 was issued to the Company by Registrar of Companies. The Company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market.
The Company has presence over 35 countries. The Company deal in Specialty pharmaceuticals finished formulations Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet, Suspension and Tablet.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Speciality Medicines Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 63,651 Cr while Market cap of Speciality Medicines Ltd is 250 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd?

As of May 13, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2255.55. On the other hand, Speciality Medicines Ltd stock price is INR ₹284.8.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Speciality Medicines Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.